Tumor necrosis in patients with TNM stage IV colorectal cancer without residual disease (R0 status) is associated with a poor prognosis

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1099-1106

  Komori, Koji ^a   Kanemitsu, Yukihide ^a   Kimura, Kenya ^a   Hattori, Norifumi ^a   Sano, Tsuyoshi ^a   Ito, Seiji ^a   Abe, Tetsuya ^a   Senda, Yoshiki ^a   Misawa, Kazunari ^a   Ito, Yuichi ^a   Uemura, Norihisa ^a   Shimizu, Yasuhiro ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Inflammatory response; Stage IV colorectal cancer; Tumor necrosis; Without residual disease (R0 status)

Indexed keywords

ADULT; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; STRATIFIED SAMPLE; SURVIVAL RATE; TUMOR NECROSIS; TUMOR VOLUME;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NECROSIS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 84875884323     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Ueno H, Murphy J, Jass JR, Mochizuki H and Talbot IC: Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40: 127-132, 2002.
2. Komori K, Hirai T, Kanemitsu Y, Shimizu Y, Sano T, Ito S, Senda Y, Misawa K, Ito Y and Kato T: Is "depth of submucosal invasion > or =1,000 micron" an important predictive factor for lymph node metastases in early invasive colorectal cancer (pT1)? Hepato-gastroenterology 57: 1123-1127, 2010.
3. Fisher ER, Palekar AS, Gregorio RM, Redmond C and Fisher B: Pathological findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). IV. Significance of tumor necrosis. Human Ppathology 9: 523-530, 1978.
4. Swinson DE, Jones JL, Richardson D, Cox G, Edwards JG and O'Byrne KJ: Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: Correlation with biological variables. Lung Cancer 37: 235-240, 2002.
5. Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, Zavada J, Yoshida M, Yamada K, Koyama T and Kanai Y: Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer 103: 1057-1065, 2010.
6. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL and Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168: 2395-2400, 2002.
7. Langner C, Hutterer G, Chromecki T, Leibl S, Rehak P and Zigeuner R: Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J Urol 176: 910-913; discussion 3-4, 2006.
8. Caruso R, Parisi A, Bonanno A, Paparo D, Quattrocchi E, Branca G, Scardigno M and Fedele F: Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas. Oncol Let letters 3: 16-18, 2012.
9. Tsujimoto M, Aozasa K, Ueda T, Morimura Y, Komatsubara Y and Doi T: Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer 62: 994-998, 1988.
10. Gao JF, Arbman G, Wadhra TI, Zhang H and Sun XF: Relationships of tumor inflammatory infiltration and necrosis with microsatellite instability in colorectal cancers. World J Gastroenterol 11: 2179-2183, 2005.
11. Guthrie GJ, Roxburgh CS, Horgan PG and McMillan DC: Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 39: 89-96, 2013.
12. Richards CH, Roxburgh CS, Anderson JH, McKee RF, Foulis AK, Horgan PG and McMillan DC: Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg 99: 287-294, 2012.
13. Pollheimer MJ, Kornprat P, Lindtner RA, Harbaum L, Schlemmer A, Rehak P and Langner C: Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol 41: 1749-1757, 2010.
14. Shimizu Y, Yasui K, Sano T, Hirai T, Kanemitsu Y, Komori K and Kato T: Treatment strategy for synchronous metastases of colorectal cancer: is hepatic resection after an observation interval appropriate? Langenbecks Arch Surg 392: 535-538, 2007.
15. Shimizu Y, Yasui K, Sano T, Hirai T, Kanemitsu Y, Komori K and Kato T: Validity of observation interval for synchronous hepatic metastases of colorectal cancer: changes in hepatic and extrahepatic metastatic foci. Langenbecks Arch Surg 393: 181-184, 2008.
16. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS and Wolmark N: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25: 2198-2204, 2007.
17. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I and de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351, 2004.
18. Monga DK and O'Connell MJ: Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. Ann Surg Oncol 13: 1021-1034, 2006.
19. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual (7th edn). Lippincott- Raven: Philadelphia, 1997.
20. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (7th edn, Rev). Kanehara shuppan: Tokyo, 2009.
21. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP and Sheahan K: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584, 1994.
22. Ueda T, Shimada E and Urakawa T: Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29: 423-429, 1994.
23. Mulcahy HE, Toner M, Patchett SE, Daly L and O'Donoghue DP: Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum 40: 326-331, 1997.
24. Hotokezaka M, Jimi S, Hidaka H, Ikeda T, Uchiyama S, Nakashima S, Tsuchiya K and Chijiiwa K: Factors influencing outcome after surgery for stage IV colorectal cancer. Surg Today 38: 784-789, 2008.
25. Shimomura M, Okajima M, Hinoi T, Egi H, Takakura Y, Kawaguchi Y, Tokunaga M, Adachi T, Tashiro H and Ohdan H: Identification of patients likely to benefit from metastasectomy in stage IV colorectal cancer. Int J Colorectal Dis 27: 1339-1346, 2012.